红景天苷对小梁网细胞细胞外基质表达及小鼠眼内压的影响
本研究探讨红景天苷能否抑制TGF-β2诱导的人小梁网细胞细胞外基质(FN、COL-IV、LN)表达,并观察其对小鼠TGF-β2诱导性高眼压的作用。结果显示30 μM红景天苷可显著且完全逆转TGF-β2诱导的ECM表达升高;每日腹腔注射40 mg/kg红景天苷(第0天或第14天开始)显著降低小鼠TGF-β2诱导的高眼压,而对对照眼眼压无影响。作者认为该酚苷可能作为POAG的新型治疗手段。
要点
- 30 μM红景天苷显著且完全逆转TGF-β2诱导的人小梁网细胞FN、COL-IV、LN表达升高。
- 每日腹腔注射40 mg/kg红景天苷(第0天或第14天开始)显著降低小鼠TGF-β2诱导的高眼压。
- 红景天苷对对照眼眼压无影响;作者认为其可能作为POAG的新型治疗手段。
核心结论
- 红景天苷能减轻TGF-β2诱导的培养人小梁网细胞ECM表达,并降低小鼠TGF-β2诱导的高眼压,作者认为该酚苷可能作为POAG的新型治疗手段。
研究设计与样本
- 体外研究:人小梁网细胞经5 ng/mL TGF-β2刺激48小时后,用红景天苷处理24小时,以定量PCR、Western blot和免疫细胞化学评估FN、COL-IV和LN表达。
- 动物实验:BALB/cJ小鼠单眼玻璃体内注射编码TGF-β2生物活性突变体的腺病毒载体(Ad.hTGF-β2226/228)诱导高眼压,未注射的对侧眼或注射Ad.Empty的眼为对照,每日腹腔注射40 mg/kg红景天苷,用TonoLab回弹式眼压计测量清醒小鼠眼压。
主要发现
- 在培养的人小梁网细胞中,TGF-β2处理使FN、COL-IV和LN表达升高(定量PCR、Western blot和免疫细胞化学评估),30 μM红景天苷显著且完全逆转上述升高。
- 每日腹腔注射40 mg/kg红景天苷,无论从第0天(与Ad.hTGF-β2226/228注射同日)还是从第14天开始,均显著降低小鼠TGF-β2诱导的高眼压。
- 红景天苷对对照眼的眼压无影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Excessive accumulation of extracellular matrix (ECM) in the trabecular meshwork (TM) reduces aqueous humor outflow, which likely contributes to elevation of IOP in primary open-angle glaucoma (POAG). Salidroside, a phenolic glycoside isolated from Rhodiola rosea is reported to prevent profibrotic responses by inhibiting Smad signaling pathway activated by TGF-β in liver, lung, and kidney tissues. We tested if salidroside can (1) inhibit TGF-β2-induced ECM expression in cultured human TM cells, and (2) lower TGF-β2-induced ocular hypertension in the mouse. METHODS: Cultured human TM cells stimulated with 5 ng/mL TGF-β2 for 48 hours were treated with salidroside for 24 hours. The expressions of fibronectin (FN), collagen type IV (COL-IV), and laminin (LN) were evaluated by quantitative PCR, Western blot, and immunocytochemistry. BALB/cJ mice were injected intravitreally with an adenoviral vector encoding a bioactive mutant of TGF-β2 (Ad.hTGF-β2226/228) in one eye to induce ocular hypertension, with the uninjected contralateral or Ad.Empty-injected eyes serving as controls. Mice were treated with a daily intraperitoneal injection of 40 mg/kg salidroside. Conscious mouse IOP values were measured using a TonoLab rebound tonometer. RESULTS: In cultured human TM cells, treatment with TGF-β2 increased expressions of FN, COL-IV, and LN, as assessed by quantitative PCR, Western blotting, and immunocytochemistry, all of which were significantly and completely ameliorated by 30 μM salidroside. Daily intraperitoneal injections of salidroside (40 mg/kg), starting either at day 0 (same day as Ad.hTGF-β2226/228 injection) or at day 14, significantly lowered TGF-β2-induced ocular hypertension in the mouse. In contrast, salidroside did not affect IOP of control eyes. CONCLUSIONS: These results demonstrated that salidroside is capable of minimizing TGF-β2-induced ECM expression in cultured human TM cells. It also reduced TGF-β2-induced ocular hypertension in the mouse. These findings indicate that this phenolic glycoside may be useful as a novel treatment for POAG.
引用
- Fan Y, Guo L, Wei J, et al. Effects of Salidroside on Trabecular Meshwork Cell Extracellular Matrix Expression and Mouse Intraocular Pressure. Invest Ophthalmol Vis Sci. 2019. PMID: 31091314. doi:10.1167/iovs.19-26585
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。